ATS CorporationATS
Recorded

ATS Corporation Jefferies Global Industrials Conference 2026

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration33 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Steve GavalasManaging Director of Industrial Technology

Okay, very good. Welcome, everyone, to Jefferies', the second day of our 2026 Industrial Conference. I'm Steve Gavales. I run the industrial technology practice at the firm. I've been here about 15 years. You're in for a treat. You have my favorite team and favorite company, not that all the other companies in this conference are not beautiful in their own right, but I've been smitten with the ATS story. At the behest of the team, we wanted to make this a bit more interactive and conversational. Maybe with that, I'd love it if you could introduce yourselves to the group, and then I can guide us with some questions. If the audience has questions, please raise your hand. We can pass mics. But we will try to wrap this up a little bit faster just so everyone doesn't feel hurried as you're making it to your next meeting.

Steve GavalasManaging Director of Industrial Technology

With that, Anne, maybe let me pass it to you.

Anne CybulskiInterim CFO

Yeah. Thanks, Steven. Hi, everyone. I'm Anne Cybulski. I'm the Interim CFO at ATS. I am one of many people at ATS who have been there for quite a long time, and have seen the growth and trajectory of the company over my 17 years there. Super happy to be here today, and I'll let Sarah introduce herself.

Sarah MooreGroup Executive for ATS Life Sciences

Super. I actually talk really loud, so I may not need this. Hi, everybody. My name is Sarah Moore. I'm a Group Executive for our life sciences business, which is about 50% of the ATS portfolio. I joined the organization about 10 months ago, coming from I'm a lifer in healthcare, so I spent 16 years at Siemens and then the last seven at Danaher, prior to joining ATS. So, it's been great to be here.

Steve GavalasManaging Director of Industrial Technology

Thanks. Wonderful. All right. Just make it a little interactive.

Steve GavalasManaging Director of Industrial Technology

Show of hands, who is very familiar with ATS? Okay, good. That's wonderful because I think where I'd like to start maybe, Sarah and Anne Cybulski, is a little level setting. Maybe just give the group a little bit of an overview on the ethos at ATS and what your North Star is.

Anne CybulskiInterim CFO

Yeah. So I'll start, and then Sarah Yeah can provide some color on our life sciences business, which, as she said, is about half of our total revenues of around CAD 3 billion a year, Canadian.

Anne CybulskiInterim CFO

We've been around as ATS since 1978, but over the years, we've grown the portfolio. We're a global automation technology player with really deep domain knowledge in the industries that we choose to serve in, which are primarily life sciences as well as food and beverage, energy, and what we call consumer and industrial, so a bit of a catchall of other industrial technology applications.

Anne CybulskiInterim CFO

Over the years, we've pivoted away from our historical participation in the transportation, sort of OEM, ICE sub-markets, and really focused on where we can provide value to our customers with automation solutions, products, services, focused on industries that have high consequence of failure, really important factors around delivery and efficiency, time to market, and generally tend to be more highly regulated. If you think about nuclear or the life sciences space, food and beverage, those all fit the bill. About 80% of our backlog is in those more highly regulated spaces at this time. Sarah, maybe put a little bit more color on the part of the business that you run, because it's a pretty exciting piece of the portfolio.

Sarah MooreGroup Executive for ATS Life Sciences

Perfect. As I mentioned, I oversee our life sciences portfolio, and if you look at life sciences, it goes all the way from discovery, which is a smart scientist has an idea, and they say, "Gosh, what do I want to do with this?" All the way through the development of whether it is a medical device, a drug, et cetera, all the way into production. How do you scale it once it passes some of the regulatory hurdles and regulatory boundaries? How do we scale this and get that capacity into the market for patients? Our portfolio in life sciences actually crosses from discovery through development into manufacturing. The bigger part of our business is in the manufacturing or production in radiopharmaceuticals, in medical devices like auto-injectors, contact lenses, automated pharmacy, spaces like that.

Sarah MooreGroup Executive for ATS Life Sciences

Because every novel therapy and medical device that reaches a patient has to be scaled in a reliable, predictable way, it creates a lot of complexity for companies. What I would say furthers that is we are operating at the edge of what is scientifically possible, and that is where ATS fits versus your average automation player. We actually play at the fringes of the frontiers of new therapies and new technologies. Radiopharmaceuticals is a great example of that. It is an enormous demand driver because, many of you know, you see the new therapies that are coming out, biologics, mRNAs, things like that. These things are very complex to manufacture and to produce, and that is where ATS comfortably sits because we manage very complex integrated solutions that bring those therapies to market at scale reliably.

Steve GavalasManaging Director of Industrial Technology

Awesome. Automation is an interesting topic in the sense that it touches everything, and it is almost a challenge of riches as far as what you can pursue. Even within your focused end markets, there are probably some areas that are more geared towards growth or maybe where you see the company doubling down as you are pursuing growth. Maybe touch on a few of those areas.

Anne CybulskiInterim CFO

Yeah. I can talk first about the broader portfolio. As I said, we have really shifted from what you might imagine as more of a custom integration shop back in 15 years ago into a broader portfolio of Services, products, and then the legacy custom integration business. Service is a really important play when it comes to automation, and Sarah can give you some great examples from the life sciences space in terms of how she sees the benefit there, both from a growth perspective, but also from a margin standpoint with our customers. Again, just to anchor back to the key end markets that we play in, we tend to like to be in markets that— Food is a little bit of a lower growth market for us, but it is good and it is stable, grows at around GDP plus 1 or 2%.

Anne CybulskiInterim CFO

But some of the markets that are in the life sciences business over time should be in the high single-digit organic growth range. Those are, again, the complexity of the markets, the growth of the end markets that we're pursuing. That's where we really serve our customers well. And with the complexity that Sarah described, as well as some of the new tools that are available to us as we provide those services, we see good opportunity from a longer-term perspective. One thing that you may be aware of is because we do have some larger projects that flow into our numbers, we do see some, call it, give and take in our bookings intake and our top line. But in this world that we operate in with the customers we serve, we view that as par for the course.

Anne CybulskiInterim CFO

But through the evolution of the portfolio, where our CEO comes from, he's seen companies with more of a 40% aftermarket entitlement. And particularly in Sarah's business, we see that as an opportunity for growth. There's a lot of secular dynamics that are working in our favor. There's a lot of noise around macro and tariffs, but we are a global, diversified company, and that has served us well in terms of where our footprint is. Sarah, maybe just speak a little bit about some of the trends you're seeing in the life sciences space to put a little bit more meat on the bones.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

More recent earnings calls

View earnings calendar